Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.

JCO precision oncology - 1 Mar 2025

Rao Mara, Merrill Madeline, Troxel Megan, Chiang Sarah, Momeni-Boroujeni Amir, Hensley Martee L, Schram Alison M

Abstract excerpt

PURPOSE: Uterine sarcomas are rare, aggressive tumors with limited chemotherapy responsiveness. Poly(ADP-ribose) polymerase inhibitors (PARPis) have emerged as targeted therapies for patients with BRCA mutations across multiple cancer types, with anecdotal responses in uterine sarcoma. This retrospective, single-center study aims to describe relevant genomic and clinical features of patients with BRCA-altered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Endometrial and Cervical Cancer Treatments
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Uterine Myomas and Treatments

Source

Open in PubMed Open full text

Identifiers

PMID: 40117531
DOI: 10.1200/PO-24-00765
PMCID: PMC11949232

Genes

BRCA2
BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors.PMID 40117531Read ↗

PARP1 expression in soft tissue sarcomas is a poor‐prognosis factor and a new potential therapeutic targetSemantic proximity Read ↗

Integrated mutational landscape analysis of uterine leiomyosarcomas.Semantic proximity Read ↗

Interrogating the Genomic Landscape of Uterine Leiomyosarcoma: A Potential for Patient BenefitSemantic proximity Read ↗

Uterine leiomyosarcoma: a review of recent advances in molecular biology, clinical management and outcome.Semantic proximity Read ↗

Next generation sequencing reveals a high prevalence of pathogenic mutations in homologous recombination DNA damage repair genes among patients with uterine sarcoma.Semantic proximity Read ↗

Proteogenomic profiling of soft tissue leiomyosarcoma reveals distinct molecular subtypes with divergent outcomes and therapeutic vulnerabilitiesSemantic proximity Read ↗

Reframing Therapeutic Development in Uterine Leiomyosarcoma: A Genomic Instability–Directed StrategySemantic proximity Read ↗

Sarcomas With RAD51B Fusions Are Associated With a Heterogeneous Phenotype.Semantic proximity Read ↗

Targeting homologous recombination deficiency in uterine leiomyosarcomaSemantic proximity Read ↗

The Future of Targeted Therapy for LeiomyosarcomaSemantic proximity Read ↗

Integrative genomic and transcriptomic analysis of leiomyosarcoma.Semantic proximity Read ↗

Hematologic complications in patients exposed to PARP inhibitorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.